Biopharmaceutical products, such as gene therapy products, therapeutic monoclonal antibodies and vaccines, are synthesised in bacterial or eukaryotic cells. Current purification techniques may not be completely effective in eliminating host residual DNA (rDNA) and concerns exist surrounding the potential of these impurities to induce undesirable immunogenic or oncogenic host responses. To support the development of safe and effective therapies, and in line with requirements by regulatory authorities, a sensitive, fast, and cost-efficient method of rDNA quantification is essential. 


In this webinar our expert discusses our HEK293 and E.Coli rDNA quantification assays comparing a quantitative PCR (qPCR) approach with a more recent digital droplet PCR (ddPCR) technique in terms of sensitivity and reproducibility as well as discussing technical challenges.


Complete the form below to listen to the webinar